Fig. 2

Gemcitabine resistance signature in PDAC cells with high ANGPTL4. (a) Cell viability was measured for MP2_ANGPTL4_KD (black), MP2_NTC (pink), and MP2_ANGPTL4_OE (turquoise) cells treated with 0, 5nM, or 12.5nM gemcitabine. Relative viability reflects normalization to cells not treated with gemcitabine. P-value asterisks: ≤0.01=**, ≤ 0.001=*** & ≤0.0001=****, unpaired, two-tailed t-test (b) Heatmap of gene expression measured by RNA-seq in MP2_ANGPTL4_KD (black/gray), MP2 (pink/light pink), and MP2_ANGPTL4_OE (turquoise/aqua) cell lines both untreated and treated with 1.5nM gemcitabine. Normalized expression of the 42 genes that resulted from an intersection of ANGPTL4 expression DEGs and gemcitabine treatment response DEGs are included in the heatmap. (c) Kaplan-Meier curve for overall survival using TCGA-PAAD data where patients were divided into quartiles with highest (red) and lowest (blue) using mean expression of the 42 genes in the intersection (40 genes were available in TCGA: KDM7a and STN1 were omitted). P-values were derived from a log-rank test